摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-甲基-1-哌嗪硫代甲酰肼 | 15970-51-1

中文名称
4-甲基-1-哌嗪硫代甲酰肼
中文别名
——
英文名称
N-methyl-piperazino-thiocarbonyl-hydrazine
英文别名
4-methylpiperazine-1-carbothiohydrazide;4-methyl-piperazine-1-carbothioic acid hydrazide;1-(N-methyl piperazine)-carbothioic acid hydrazide;4.4-(3-Methyl-3-azapentamethylen)thiosemicarbazid;4-Methyl-piperazinothiocarbonyl-hydrazin
4-甲基-1-哌嗪硫代甲酰肼化学式
CAS
15970-51-1
化学式
C6H14N4S
mdl
MFCD19201332
分子量
174.27
InChiKey
JNGXJKJTJUBQSH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    268.6±50.0 °C(Predicted)
  • 密度:
    1.212±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.8
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    76.6
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933599090

SDS

SDS:21f1de1bb40d891ad4852ed7e3c1d817
查看

反应信息

  • 作为反应物:
    描述:
    4-甲基-1-哌嗪硫代甲酰肼 作用下, 以 乙醇 为溶剂, 反应 1.17h, 生成 1-acetyl-3-(4-methyl-piperazino)-4-acetylmercapto-5-(4-bromophenyl)-pyrazole
    参考文献:
    名称:
    Synthesis and Reactivity of 2-Pyrrolidino-, 2-N-Methylpiperazino-, 2-Piperidino-, and 2-Morpholino-1,3,4-thiadiazines
    摘要:
    A variety of 2‐pyrrolidino‐, 2‐N‐methylpiperazino‐, 2‐piperidino‐, and 2‐morpholino‐1,3,4‐thiadiazines were prepared by cyclocondensation of phenacyl halides with thiosemicarbazides. Heating of the products resulted in desulfurization and formation of pyrazoles. The rate of this process strongly depends on the substitution pattern of the 1,3,4‐thiadiazines.
    DOI:
    10.1002/jhet.2072
  • 作为产物:
    描述:
    咪唑-1-基-(4-甲基-哌嗪-1-基)-甲硫酮 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以61%的产率得到4-甲基-1-哌嗪硫代甲酰肼
    参考文献:
    名称:
    COMPOUNDS AND METHOD FOR TREATMENT OF CANCER
    摘要:
    本发明涉及一种I式化合物:和/或其药学上可接受的盐、水合物、溶剂合物、互变异构体、光学异构体或其组合物,一种包含该硫脲半胱氨酸的组合物,一种其治疗癌症的给药方法以及使用该化合物的方法。
    公开号:
    US20080171744A1
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS<br/>[FR] DÉRIVÉS DE THIOSEMICARBAZONE HÉTÉROCYCLIQUES ET LEURS APPLICATIONS THÉRAPEUTIQUES
    申请人:NANT HOLDINGS IP LLC
    公开号:WO2017024315A1
    公开(公告)日:2017-02-09
    Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
    本文介绍了制备各种杂环硫脲类衍生物的药物化合物、组合物和方法。考虑到这些化合物适用于抑制或减少细胞生长或增殖,因此在制造用于治疗肿瘤性疾病的药物方面具有益处。
  • COMPOUNDS AND METHOD FOR TREATMENT OF CANCER
    申请人:Danter Wayne R.
    公开号:US20080171744A1
    公开(公告)日:2008-07-17
    The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    本发明涉及一种I式化合物:和/或其药学上可接受的盐、水合物、溶剂合物、互变异构体、光学异构体或其组合物,一种包含该硫脲半胱氨酸的组合物,一种其治疗癌症的给药方法以及使用该化合物的方法。
  • Inhibitor Compounds and Cancer Treatment Methods
    申请人:Danter Wayne R.
    公开号:US20100015140A1
    公开(公告)日:2010-01-21
    A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    一种协同作用的抗癌药物和治疗化合物的组合,例如 mTOR-Rictor 复合物抑制剂、丝氨酸 473 磷酸化抑制剂、AKT2 抑制剂或其组合,用于治疗癌症的方法和用途。还包括一种硫脲半胱氨酮的方法和用途,用于治疗需要的哺乳动物中的癌症,其特征是过度表达 RAS、EGFR 突变和/或 AKT2 过度表达。
  • [EN] THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS<br/>[FR] COMPOSÉS INHIBITEURS ET PROCÉDÉS DE TRAITEMENT DU CANCER
    申请人:CRITICAL OUTCOME TECHNOLOGIES
    公开号:WO2010006438A1
    公开(公告)日:2010-01-21
    A synergistically effective combination of an anti-cancer agent and a thiosemicarbazone therapeutic compound of formula (I), which is an mTOR-Rictor inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof, characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2.
    一种抗癌剂和一种式(I)的硫脲半胱氨酸类治疗化合物的协同有效组合,该化合物是mTOR-Rictor抑制剂、丝氨酸473磷酸化抑制剂、AKT2抑制剂或其组合物,用于治疗癌症,以及其方法和用途。还包括一种硫脲半胱氨酸类用于治疗需要的哺乳动物中的癌症的方法和用途,其特征是RAS的过表达,EGFR突变和/或AKT2的过表达。
  • Compounds and method for treatment of cancer
    申请人:Danter Wayne R
    公开号:US08466151B2
    公开(公告)日:2013-06-18
    The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II) and the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    本发明涉及一种化合物,其化学式为(I),和/或其药学上可接受的盐、水合物、溶剂合物、互变异构体、光学异构体、E-异构体、Z-异构体或其组合物,其中X选自S或O;R5选自取代或未取代的芳香族基团,取代或未取代的杂环芳基团,或(式II),其余取代基在此处描述;以及包含硫脲半胱氨酸和/或半胱氨酮的组合物。本发明还涉及一种硫脲半胱氨酸和/或半胱氨酮的给药方法;以及用于治疗癌症的应用。
查看更多